Skip to main content

June 10: VDP Formulary, CAD, MCO Search Realignment Now Active

Dot gov

Official websites use the Texas HHS logo.
The Texas HHS logo means this is an official website of Texas Health and Human Services.

HTTPS

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

3. References

  1. IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www-micromedexsolutions-com.libproxy.uthscsa.edu/ (cited: May 30, 2023).
  2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2023. Available at: http://clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed May 30, 2023.
  3. Mecasermin [rDnA origin] injection (Increlex®) package insert. Ipsen Biopharmaceuticals, Inc., May 2020.
  4. Chernausek SD, Backeljauw PF, Frane J, et al for the GH Insensitivity Syndrome Collaborative Group. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab. 2007;92(3):902-10.
  5. Bright GM, Mendoza JR, Rosenfeld RG. Recombinant human insulin-like growth factor-1 treatment: ready for primetime. Endocrinol Metab Clin N Am. 2009;38:625-38.
  6. Midyett LK, Rogol AD, Van Meter QL, et al. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels:  first-year results from a randomized clinical trial. J Clin Endocrinol Metab.  2010;95: 611–9.
  7. Cohen J, Blethen S, Kuntze J, et al. Managing the child with severe primary insulin-like growth factor-1 deficiency (IGFD): IGFD diagnosis and management. Drugs R D. 2014;14:25-9.